Apolipoproten E (apoeE) is a major genetic risk factor for the development of Alzheimer’s disease, yet it tends to be understudied as a potential druggable target for the mind-robbing neurodegenerative disease. Now a research team reports that a novel apoE antagonist blocks apoE interaction with N-terminal amyloid precursor protein (APP) and reduces hallmark Alzheimer’s-associated pathologies.
Related Posts
Order Antibiotics online
June 8, 2024Buying antibiotics online
June 8, 2024How do antibiotics work?
June 8, 2024Flagyl: a beacon of hope in the fight against trichomoniasis
February 17, 2024Metronidazole for bacterial infection
February 1, 2023